264 related articles for article (PubMed ID: 10933953)
1. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
4. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Miyatake S; Martuza RL; Rabkin SD
Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor gene therapy using suicide genes].
Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
Medicina (B Aires); 1998; 58(2):185-8. PubMed ID: 9706253
[TBL] [Abstract][Full Text] [Related]
6. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
8. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.
Li S; Tokuyama T; Yamamoto J; Koide M; Yokota N; Namba H
Cancer Gene Ther; 2005 Jul; 12(7):600-7. PubMed ID: 15775995
[TBL] [Abstract][Full Text] [Related]
9. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
10. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.
Ezzeddine ZD; Martuza RL; Platika D; Short MP; Malick A; Choi B; Breakefield XO
New Biol; 1991 Jun; 3(6):608-14. PubMed ID: 1655012
[TBL] [Abstract][Full Text] [Related]
12. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
13. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Boviatsis EJ; Scharf JM; Chase M; Harrington K; Kowall NW; Breakefield XO; Chiocca EA
Gene Ther; 1994 Sep; 1(5):323-31. PubMed ID: 7584098
[TBL] [Abstract][Full Text] [Related]
15. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
16. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
17. Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene.
Tamura K; Tamura M; Ikenaka K; Yoshimatsu T; Miyao Y; Nanmoku K; Shimizu K
Gene Ther; 2001 Feb; 8(3):215-22. PubMed ID: 11313793
[TBL] [Abstract][Full Text] [Related]
18. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Aghi M; Chou TC; Suling K; Breakefield XO; Chiocca EA
Cancer Res; 1999 Aug; 59(16):3861-5. PubMed ID: 10463570
[TBL] [Abstract][Full Text] [Related]
19. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
20. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
